Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/dom.13211 http://scihub22266oqcxt.onion/10.1111/dom.13211 C5947308!5947308!29316197     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Diabetes+Obes+Metab 2018 ; 20 (5): 1311-5 Nephropedia Template TP {{tp|p=29316197|t=2018. Tofogliflozin decreases body fat mass and improves peripheral insulin resistance |pdf=|usr=}}{{29316197}} gab.com Text Tofogliflozin decreases body fat mass and improves peripheral insulin resistance JO: Diabetes Obes Metab http://www.kidney.de/pget.php?&tw=1&pmid=29316197 #FOAvip The impact of tofogliflozin, a sodium?glucose co?transporter?2 inhibitor, on peripheral glucose uptake in patients with type 2 diabetes mellitus (T2DM) was investigated using the hyperinsulinaemic?euglycaemic clamp method in a single?arm, open?label study. The following variables were compared between before and after tofogliflozin administration for 12 weeks in 16 patients with T2DM who were receiving dipeptidyl peptidase?4 inhibitor treatment: body weight (BW); blood pressure; glucose metabolism; liver function; lipid profile; and body composition. Peripheral glucose uptake (M value and M/I ratio) was examined by the hyperinsulinaemic?euglycaemic clamp method. After 12 weeks, there was a significant decrease (P < .001) in glycated haemoglobin, BW, body fat mass and lean body mass. Peripheral glucose uptake, which indicates insulin sensitivity, increased significantly (M value by 0.90 and M/I ratio by 0.49; both P < .05). The change in the M value after 12 weeks of tofogliflozin therapy was correlated with the change in body fat mass (P < .05). Tofogliflozin significantly improved insulin sensitivity and peripheral glucose uptake in patients with T2DM. These improvements were significantly correlated with reduction in body fat mass. Twit Text FOAVip Tofogliflozin decreases body fat mass and improves peripheral insulin resistance ????Diabetes Obes Metab http://www.kidney.de/pget.php?&tw=1&pmid=29316197 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29316197 #FOAvip English Wikipedia <ref>{{Cite pmid|29316197}}</ref> Tofogliflozin decreases body fat mass and improves peripheral insulin resistance #MMPMID29316197 Matsuba R; Matsuba I; Shimokawa M; Nagai Y; Tanaka Y Diabetes Obes Metab 2018[May]; 20 (5): 1311-5 PMID29316197show ga The impact of tofogliflozin, a sodium?glucose co?transporter?2 inhibitor, on peripheral glucose uptake in patients with type 2 diabetes mellitus (T2DM) was investigated using the hyperinsulinaemic?euglycaemic clamp method in a single?arm, open?label study. The following variables were compared between before and after tofogliflozin administration for 12 weeks in 16 patients with T2DM who were receiving dipeptidyl peptidase?4 inhibitor treatment: body weight (BW); blood pressure; glucose metabolism; liver function; lipid profile; and body composition. Peripheral glucose uptake (M value and M/I ratio) was examined by the hyperinsulinaemic?euglycaemic clamp method. After 12 weeks, there was a significant decrease (P < .001) in glycated haemoglobin, BW, body fat mass and lean body mass. Peripheral glucose uptake, which indicates insulin sensitivity, increased significantly (M value by 0.90 and M/I ratio by 0.49; both P < .05). The change in the M value after 12 weeks of tofogliflozin therapy was correlated with the change in body fat mass (P < .05). Tofogliflozin significantly improved insulin sensitivity and peripheral glucose uptake in patients with T2DM. These improvements were significantly correlated with reduction in body fat mass. äTofogliflozin decreases body fat mass and improves peripheral insulin (epmc).pdf DeepDyve Pubget Overpricing